Savara Inc (NASDAQ:SVRA) insider Jaakko Taneli Jouhikainen sold 25,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $12.85, for a total transaction of $321,250.00. Following the completion of the sale, the insider now directly owns 219,216 shares of the company’s stock, valued at $2,816,925.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of Savara Inc (NASDAQ:SVRA) traded down $0.01 during midday trading on Wednesday, hitting $10.52. The company’s stock had a trading volume of 128,557 shares, compared to its average volume of 162,206. The company has a market capitalization of $320.87, a PE ratio of -3.13 and a beta of -0.18. Savara Inc has a 12 month low of $4.60 and a 12 month high of $17.19. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.15 and a current ratio of 9.15.
Several hedge funds and other institutional investors have recently modified their holdings of SVRA. Consonance Capital Management LP bought a new position in shares of Savara during the fourth quarter valued at $40,899,000. VHCP Management II LLC bought a new position in shares of Savara in the fourth quarter valued at about $18,691,000. BlackRock Inc. raised its holdings in shares of Savara by 642.4% in the fourth quarter. BlackRock Inc. now owns 499,512 shares of the company’s stock valued at $7,412,000 after buying an additional 432,225 shares during the last quarter. Lyon Street Capital LLC raised its holdings in shares of Savara by 53.4% in the fourth quarter. Lyon Street Capital LLC now owns 779,554 shares of the company’s stock valued at $11,569,000 after buying an additional 271,214 shares during the last quarter. Finally, Sectoral Asset Management Inc bought a new position in shares of Savara in the fourth quarter valued at about $2,374,000. 38.25% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/03/14/savara-inc-svra-insider-sells-321250-00-in-stock.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.